US 12,269,898 B2
Transthyretin immunoglobulin fusions
Kenneth Walker, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 16/753,216
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Oct. 3, 2018, PCT No. PCT/US2018/054237
§ 371(c)(1), (2) Date Apr. 2, 2020,
PCT Pub. No. WO2019/070901, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/568,217, filed on Oct. 4, 2017.
Prior Publication US 2020/0317795 A1, Oct. 8, 2020
Int. Cl. C07K 19/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C07K 16/00 (2006.01); C12N 15/63 (2006.01)
CPC C07K 19/00 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/47 (2013.01); C07K 16/00 (2013.01); C07K 16/28 (2013.01); C07K 16/2878 (2013.01); C07K 2317/35 (2013.01); C07K 2319/00 (2013.01); C12N 15/63 (2013.01)] 33 Claims
 
1. A homodimer fusion protein comprising two antibodies linked to a transthyretin (TTR) protein complex,
wherein the antibodies bind tumor necrosis factor-related apoptosis-inducing ligand receptor-2 (TRAILR2), and
wherein the TTR protein complex comprises four TTR subunits.